173 related articles for article (PubMed ID: 16469541)
1. Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Inglis S; Stewart S
Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541
[TBL] [Abstract][Full Text] [Related]
2. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Rupp H; Zarain-Herzberg A; Maisch B
Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
[TBL] [Abstract][Full Text] [Related]
3. Metabolic modulation: a new therapeutic target in treatment of heart failure.
Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
[TBL] [Abstract][Full Text] [Related]
4. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Lee L; Horowitz J; Frenneaux M
Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
[TBL] [Abstract][Full Text] [Related]
5. Calcium channel blockers.
Dipalma JR
Am Fam Physician; 1983 Feb; 27(2):283-5. PubMed ID: 6829383
[No Abstract] [Full Text] [Related]
6. Metabolic management of ischaemic heart disease.
Chierchia SL; Fragasso G
Eur Heart J; 1993 Nov; 14 Suppl G():2-5. PubMed ID: 7904560
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses.
Willoughby SR; Chirkov YY; Kennedy JA; Murphy GA; Chirkova LP; Horowitz JD
Eur J Pharmacol; 1998 Sep; 356(2-3):207-13. PubMed ID: 9774251
[TBL] [Abstract][Full Text] [Related]
8. Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.
Chong CR; Sallustio B; Horowitz JD
Cardiovasc Drugs Ther; 2016 Aug; 30(4):399-405. PubMed ID: 27106834
[TBL] [Abstract][Full Text] [Related]
9. Chronic stable angina pectoris.
Jawad E; Arora R
Dis Mon; 2008 Sep; 54(9):671-89. PubMed ID: 18725007
[No Abstract] [Full Text] [Related]
10. Perhexiline.
Ashrafian H; Horowitz JD; Frenneaux MP
Cardiovasc Drug Rev; 2007; 25(1):76-97. PubMed ID: 17445089
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent.
Cole PL; Beamer AD; McGowan N; Cantillon CO; Benfell K; Kelly RA; Hartley LH; Smith TW; Antman EM
Circulation; 1990 Apr; 81(4):1260-70. PubMed ID: 2180591
[TBL] [Abstract][Full Text] [Related]
12. Metabolic agents in the management of diabetic coronary patients: a new era.
Marazzi G; Volterrani M; Rosano GM
Int J Cardiol; 2008 Jun; 127(1):124-5. PubMed ID: 18199501
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine: a review of its use in chronic stable angina pectoris.
Siddiqui MA; Keam SJ
Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
[TBL] [Abstract][Full Text] [Related]
14. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina.
César LA; Gowdak LH; Mansur AP
Curr Pharm Des; 2009; 15(8):841-9. PubMed ID: 19275648
[TBL] [Abstract][Full Text] [Related]
15. The metabolic treatment of coronary artery disease and heart failure.
Di Napoli P
Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645
[No Abstract] [Full Text] [Related]
16. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on ranolazine in chronic stable angina pectoris.
Siddiqui MA; Keam SJ
Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
[TBL] [Abstract][Full Text] [Related]
18. Ranolazine and other antianginal therapies in the era of the drug-eluting stent.
Berger P
JAMA; 2004 Jan; 291(3):365-7. PubMed ID: 14734600
[No Abstract] [Full Text] [Related]
19. Chronic angina: new medical options for treatment.
McCullough PA
Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease.
Killalea SM; Krum H
Am J Cardiovasc Drugs; 2001; 1(3):193-204. PubMed ID: 14728034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
